What will the future world of GLP-1 drugs look like? From Eli Lilly's Foundayo to triple-strength Wegovy, discover the ...

While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule ...

This is read by an automated voice. Please report any issues or inconsistencies here. Ozempic, Zepbound, and Wegovy are now household names. And as these GLP-1 medications have exploded in popularity, ...

FormBlends' platform extends beyond GLP-1 receptor agonists into the broader peptide therapy landscape, which reached $140.86 billion globally in 2025 and is projected to grow to $260.25 billion by ...

Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral ...

Ozempic, and the class of weight loss drugs it has come to embody, has left its imprint seemingly everywhere: On the lives of millions of patients who’ve lost unprecedented amounts of weight. On ...

HONG KONG, Feb. 19, 2026 /PRNewswire/ -- As the multi-billion-dollar obesity treatment market continues to search for new therapeutic approaches beyond GLP-1–based treatments, Clearmind Medicine ...

LONDON, GREATER LONDON, UNITED KINGDOM, March 4, 2026 /EINPresswire.com/ -- "The GLP-1 Receptor Agonist market is dominated by a mix of global pharmaceutical leaders ...

FormBlends' platform extends beyond GLP-1 receptor agonists into the broader peptide therapy landscape, which reached $140.86 ...